Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

10.020
-0.230-2.24%
Volume:1.78M
Turnover:18.09M
Market Cap:10.54B
PE:-27.07
High:10.320
Open:10.150
Low:9.945
Close:10.250
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:1.18
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-18.45%
ROA:-14.45%
PB:4.67
PE(LYR):-27.07
PS:4454.37

Loading ...

HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%

Tiger Newspress
·
Mar 27

HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.

Tiger Newspress
·
Mar 26

HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%

Tiger Newspress
·
Mar 24

BRIEF-Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026

Reuters
·
Mar 17

Ascletis targets Q3 2026 FDA IND filing for ASC39 oral obesity tablets

Reuters
·
Mar 17

ASCLETIS-B Selects Oral Amylin Receptor Agonist ASC39 as Clinical Candidate, Demonstrating Eloralintide-Like Selectivity and Efficacy in Preclinical Models

Stock News
·
Mar 17

Ascletis Pharma Inc - Expects to Submit Ind Application to U.S. FDA for Asc39 Oral Tablets in Q3 2026

THOMSON REUTERS
·
Mar 17

Ascletis says ASC39 delivered 6.6% placebo-adjusted weight loss in obese rats and targets US FDA IND filing in Q3 2026

Reuters
·
Mar 17

HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.

Tiger Newspress
·
Mar 17

BRIEF-Ascletis Announces Positive Topline Results from U.S. Phase II for Its Ultra-Long-Acting GLP-1R Agonist ASC30 for Obesity

Reuters
·
Mar 10

Ascletis Pharma Inc - Asc30 Achieves 7.5% Placebo-Adj Mean Weight Loss at Week 16 After Three Monthly Doses

THOMSON REUTERS
·
Mar 10

Ascletis Pharma Inc - No Discontinuations Due to Adverse Events for Asc30 or Placebo

THOMSON REUTERS
·
Mar 10

Ascletis Pharma Inc - Asc30 Demonstrates Safety Profile Consistent With Glp-1 Drug Class

THOMSON REUTERS
·
Mar 10

Ascletis Pharma Inc: Asc30 Phase Ii Study Achieved Its Primary Endpoint

THOMSON REUTERS
·
Mar 10

Ascletis Pharma Inc - Asc30 Maintains Weight Loss for Four Months After Final Monthly Dose

THOMSON REUTERS
·
Mar 10

Ascletis Announces Positive Topline Results From U.S. Phase Ii, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule Glp-1R Agonist Asc30 for Obesity

THOMSON REUTERS
·
Mar 10

ASCLETIS-B's Long-Acting GLP-1 Candidate Shows Promising Weight Loss in U.S. Phase II Trial

Stock News
·
Mar 10

Ascletis reports Phase II ASC30 depot achieves 8% placebo-adjusted weight loss at week 16

Reuters
·
Mar 10

Ascletis Pharma Inc. (01672) Releases February 2026 Monthly Return on Movements in Securities

Bulletin Express
·
Mar 03